Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 15/20 | 0.60 |
| ▸ | HTR2A | P28223 | 14/20 | 0.60 |
| ▸ | HTR2B | P41595 | 5/20 | 0.60 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966073 | 0.83 | CYP3A4 (0.41) | HTR2CHTR2AHTR2BNAMPT | |
| SCHEMBL3958486 | 0.78 | HTR2C (0.71) | HTR2CHTR2AHTR2B | |
| SCHEMBL3958488 | 0.78 | HTR2C (0.71) | HTR2CHTR2AHTR2B | |
| SCHEMBL3962660 | 0.77 | HTR2C (0.70) | HTR2CHTR2AHTR2B | |
| SCHEMBL3961408 | 0.74 | HTR2C (0.71) | HTR2CHTR2AHTR2B | |
| SCHEMBL3962679 | 0.74 | HTR2C (0.71) | HTR2CHTR2AHTR2B | |
| SCHEMBL12802329 | 0.74 | HTR2C (0.83) | HTR2CHTR2AHTR2B | |
| SCHEMBL3965543 | 0.74 | HTR2C (0.67) | HTR2CHTR2AHTR2B | |
| SCHEMBL12802908 | 0.72 | HTR2C (0.79) | HTR2CHTR2AHTR2B | |
| Fumaric Acid SCHEMBL3957103 | 0.71 | HTR2C (0.60) | HTR2CHTR2AHTR2BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476687-B2 | Substituted furo[2,3-g]indazoles for the treatment of glaucoma | ALCON, INC. (CH) | 2009-01-13 | — | — | US | disclosed |
| US-20090012291-A1 | SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20070135430-A1 | Substituted furo[2,3-g]indazoles for the treatment of glaucoma | ALCON, INC. (CH) | 2007-06-14 | — | — | US | disclosed |
| WO-2005053688-A1 | SUBSTITUTED FURO[2,3-G] INDAZOLES FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135430-A1 | Substituted furo[2,3-g]indazoles for the treatment of glaucoma | PTGIS, PTGIR, PTGS2 | HTR2C 646/4885HTR2A 1195/4885HTR2B 1055/4885 |
| US-20090012291-A1 | SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA | PTGIS, PTGIR, PTGS2 | HTR2C 646/4885HTR2A 1195/4885HTR2B 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.